Navigation Links
BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
Date:12/8/2008

PRINCETON, N.J., Dec. 8 /PRNewswire/ -- BioWa, Inc., announced today that it licensed to GlaxoSmithKline (NYSE: GSK) its POTELLIGENT(R) Technology for use in developing and commercializing select GSK antibodies with enhancement of antibody-dependent cellular cytotoxicity (ADCC).

"GSK is recognized as a key player in the field of antibody drug discovery," said Dr. Masamichi Koike, BioWa President and CEO. "We believe this represents an important opportunity to promote the development of more effective targeted treatments for debilitating diseases where enhanced ADCC might offer a significant therapeutic benefit."

Under the terms of the agreement, BioWa will provide GSK with non- exclusive commercial rights to use the technology for multiple antibodies. In return, BioWa will receive technology access fees, and may receive milestone payments and royalties from resulting products which are developed by GSK. Additional terms were not disclosed.

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT(R) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(R) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT(R) antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platform consists of POTELLIGENT(R) and COMPLEGENT(TM) Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT(R) and COMPLEGENT(TM) Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is focused on development of ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at http://www.biowa.com.

POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.


'/>"/>
SOURCE BioWa, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
2. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
3. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
4. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
5. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
6. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
7. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
8. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
9. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
10. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
11. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Part of 5m$ Investment in Integrated ... ... LLC today announced that it had successfully completed the expansion ... have increased the Screening Collection to over 400,000. The new ... of the company. This expansion, complemented by new robotics and ...
(Date:11/30/2016)... ... 30, 2016 , ... Energetiq Technology, a world leader in ... ultra-bright, Laser-Driven Light Source, the EQ-77, at the MRS Fall Exhibit 2016. , ... higher radiance and irradiance from a truly broadband white light source. The EQ-77 ...
(Date:11/30/2016)... ... ... With growth rates averaging more than 30% each year, Random42 has quickly ... their expansion in their new office space. The new office has a fantastic location ... creative industries, so Random42 Scientific Communication will fit right in. , Ben Ramsbottom, ...
(Date:11/30/2016)... Connecticut , November 30, 2016 ... die integrierte Medikamententdeckung    ... , , ... Prüfbibliothek erfolgreich erweitert zu haben. Zusätzliche 150.000 neuartige Substanzen ... Substanzen wurden sorgfältig ausgewählt, um die starken Entdeckungsfähigkeiten des ...
Breaking Biology Technology:
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
Breaking Biology News(10 mins):